PURPOSE: This study aimed to assess how @entity55 incidence, health care resource utilization, costs, and hospital length of stay differ by age category in the United States. METHODS: A retrospective cross-sectional analysis of the Medical Expenditure Panel Survey database was conducted from 2007 to 2011 for @entity1 with @entity55 . Study outcomes were @entity55 incidence, annual health care utilization, and expenditures across 5 age groups. Early trends of outcomes in the period after introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) (2011) were compared with the pre-PCV13 period (2007-2009). FINDINGS: @entity55 incidence rates for the 1790 @entity1 ranged from 9.2 to 33.0 per 1000 @entity1 . @entity1 <5 years old had the highest incidence rate at 33.0 per 1000 @entity1 , followed by @entity1 >= 65 years old (27.2 per 1000 @entity1 ) and @entity1 >= 45 to <65 years old (14.4 per 1000 @entity1 ). The percentages of @entity1 with @entity55 -related hospitalization were 26%, 7%, 15%, 24%, and 46%, respectively (P < 0.0001). Mean (SD) days in hospital stay were 1.73 (0.08), 0.31 (0.50), 0.58 (0.10), 1.86 (0.29), and 3.05 (0.33), respectively (P < 0.05), for @entity1 <5, >= 5 to <18, >= 18 to <45, >= 45 to <65, and >= 65 years old. Mean total @entity55 -related medical costs in @entity1 aged <5 years ( 3376; P = 0.009), >= 45 to  <=65 years ( 4726; P < 0.0001), and >65 years ( 7206; P < 0.0001) were significantly higher compared with @entity1 >= 5 to <18 years old ( 1175) after controlling for covariates. Compared with the pre-PCV13 period (2007-2009; n = 1075), a 16% decrease in incidence, a 27% decrease length of stay in hospital, and a 22% decrease in medical costs were observed in the post-PCV13 period (2011; n = 382), although these differences were not statistically significant (P > 0.05). IMPLICATIONS: @entity55 remains a disease with significant burden in the United States, and clinical and economic outcomes varied widely by age. Hospitalization for @entity55 has a considerable effect on economic burden, particularly for the very young (<5 years old), middle-aged (>= 45 to <65 years old), and elderly (>= 65 years old) populations. A trend toward reductions in @entity55 incidence and associated medical costs was observed after the PCV13 was introduced, although these findings were not statistically significant.

Direct Medical Costs and Utilization of Health Care Services to Treat XXXX in the United States: An Analysis of the 2007-2011 Medical Expenditure Panel Survey.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia', 'Pneumonia']
@entity55 :: (MESH:D011014,Disease) :: ['Pneumonia']
